IPODD project discusses progress with inflammatory bowel disease
12 April 2011
Experts from 11 countries are gathering in Rome this week
(April 13-16) to discuss innovative strategies for studying and treating
inflammatory bowel diseases (IBDs).
The meeting is organized by the EU-funded project IPODD, a 3-year
consortium launched in 2008 for research on IBDs.
IPODD (Intestinal Proteases: Opportunity for Drug Discovery) has
put together the expertise of 13 research teams across 7 countries
(Czech Republic, Germany, Ireland, Italy, Netherlands, New Zealand,
UK) coordinated by Prof. David Grundy at the University of
Sheffield. The project was funded by the EU seventh framework
program (FP7) with €3 million and will expire in July 2011.
IBDs are chronic disorders of the gastrointestinal tract that
include Crohn's disease and ulcerative colitis. In both diseases
symptoms range from mild (eg abdominal discomfort and diarrhoea) to
severe (abdominal pain, bleeding, anaemia, weight loss and others).
Some cases may require surgery for eliminating parts of the
IBDs affect 1-5 people out of 1000 in Europe. Most patients
develop symptoms as a teenager and have alternating periods of
remission and relapse (flares) during their entire life. IBDs are an
important cause of disability and morbidity, interfering with the
quality of life of thousands people for many years.
The meeting's goals are to disseminate and discuss the latest
findings from IPODD; and review the most promising avenues in IBD
research, including work on proteases, probiotic intervention and
Representatives from the European Federation of Crohn's and
Colitis Associations (EFCCA) will also bring the patients' angle on
IPODD (Intestinal Proteases: Opportunity for Drug Discovery)
project website: www.ipodd.eu